NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Johnson & Johnson JNJ
19 fiscal years on record · USD · FY2025 reported · SEC filings only
18 YEARS OF DIVIDEND GROWTH
In brief
What this company does
Written from the business description in JOHNSON & JOHNSON's annual report to the U.S. Securities and Exchange Commission, filed 11 February 2026. Every sentence was checked against that document before publication.
Growth
USD 94.2B
Revenue, FY2025 · full 19-year series below
Revenue $B
Net income $B
FY2025 · Revenue 94.2 · Net income 26.8
Compound annual growth
+5.6%
+2.7%
+3.0%
+2.9%
+14.3%
+12.7%
+5.7%
+4.8%
+17.9%
+14.9%
+7.2%
+5.7%
+4.9%
+5.2%
+5.7%
+6.1%
−0.5%
+13.1%
+1.2%
+9.3%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +2.7% a year over five years — but profit grew faster: net income at +12.7%, earnings per share at +14.9%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
28 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 34.6% · Net 28.5%
ROE
Not available in our data for this period.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 94.2 | 88.8 | 85.2 | 80.0 | 78.7 | 82.6 | 82.1 | 81.6 | 76.5 | 71.9 | 70.1 | 74.3 | 71.3 | 67.2 | 65.0 | 61.6 | 61.9 | 63.7 | 61.1 |
| Operating income $B | 32.6 | 16.7 | 15.1 | 19.4 | 19.2 | 16.5 | 17.3 | · | · | · | · | 21.6 | 16.4 | 15.0 | 13.8 | 17.7 | 16.6 | · | · |
| EBITDA $B | 40.1 | 24.0 | 22.5 | 26.3 | 26.6 | 23.7 | 24.3 | · | · | · | · | 25.5 | 20.5 | 18.6 | 16.9 | 20.6 | 19.4 | · | · |
| Income tax $B | 5.8 | 2.6 | 1.7 | 3.0 | 1.4 | 1.8 | 2.2 | 2.7 | 16.4 | 3.3 | 3.8 | 4.2 | 1.6 | 3.3 | 2.7 | 3.6 | 3.5 | 4.0 | 2.7 |
| Net income $B | 26.8 | 14.1 | 35.2 | 17.9 | 20.9 | 14.7 | 15.1 | 15.3 | 1.3 | 16.5 | 15.4 | 16.3 | 13.8 | 10.9 | 9.7 | 13.3 | 12.3 | 12.9 | 10.6 |
| Free cash flow $B | 19.7 | 19.8 | 18.2 | 17.2 | 19.8 | 20.2 | 19.9 | 18.5 | 17.8 | 15.5 | 16.1 | 15.0 | 13.8 | 12.5 | 11.4 | 14.0 | 14.2 | 11.9 | 12.1 |
| EPS, diluted $ | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 | 5.48 | 5.70 | 4.81 | 3.86 | 3.49 | 4.78 | 4.40 | 4.57 | 3.63 |
| Dividend / sh $ | 5.14 | 4.91 | 4.70 | 4.45 | 4.19 | 3.98 | 3.75 | 3.54 | 3.32 | 3.15 | 2.95 | 2.76 | 2.59 | 2.40 | 2.25 | 2.11 | 1.93 | 1.79 | 1.62 |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Johnson & JohnsonvsELI Lilly & Co.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsMerck & Co. Inc.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsPfizer Inc.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsAbbVie Inc.Same industry: Pharmaceutical PreparationsJohnson & JohnsonvsAstrazeneca PLCSame industry: Pharmaceutical PreparationsJohnson & JohnsonvsNovartis AGSame industry: Pharmaceutical PreparationsJohnson & JohnsonvsBristol Myers Squibb Co.Same industry: Pharmaceutical Preparations
Provenance
Company facts, as filed
How we verify · 0 failures in 93 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inNew Jersey
Fiscal year endsJanuary 3
Data on record since2007